PMID- 35721172
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Aqueous Extract of Guava (Psidium guajava L.) Leaf Ameliorates Hyperglycemia by 
      Promoting Hepatic Glycogen Synthesis and Modulating Gut Microbiota.
PG  - 907702
LID - 10.3389/fphar.2022.907702 [doi]
LID - 907702
AB  - Type 2 diabetes mellitus (T2DM) is a major global health concern. Psidium guajava 
      L. (guava) is widely used for food as well as a folk medicine. Previous studies 
      have shown its anti-diabetic and anti-inflammatory properties. However, the 
      underlying mechanisms remains to be elusive. In this study, we assessed the 
      potential therapeutic effects of aqueous extract of guava leaves (GvAEx) on T2DM 
      and explored their potential mechanisms in vivo and in vitro. GvAEx was gavage 
      administered for 12 weeks in diabetic db/db mice. Our results have demonstrated 
      that GvAEx significantly lowered fasting plasma glucose levels (p < 0.01) and 
      improved glucose tolerance and insulin sensitivity (p < 0.01, p < 0.05, 
      respectively). Additionally, GvAEx increased hepatic glycogen accumulation, 
      glucose uptake and decreased the mRNA expression levels of gluconeogenic genes. 
      Furthermore, GvAEx-treatment caused higher glucose transporter 2 (GLUT2) 
      expression in the membrane in hepatocytes. Notably, for the first time, we have 
      elaborated the possible mechanism of the hypoglycemic effect of GvAEx from the 
      perspective of intestinal microbiota. GvAEx has significantly changed the 
      composition of microbiota and increased short chain fatty acid (SCFA) -producing 
      Lachnospiraceae family and Akkermansia genus in the gut. Taken together, GvAEx 
      could alleviate hyperglycemia and insulin resistance of T2DM by regulating 
      glucose metabolism in the liver and restoring the gut microbiota. Thus, GvAEx has 
      the potential for drug development against T2DM.
CI  - Copyright (c) 2022 Chu, Zhang, Wang, Xie, Chen, Zeng, Zhou and Hu.
FAU - Chu, Shuzhou
AU  - Chu S
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, Metabolic 
      Syndrome Research Center, Department of Metabolism and Endocrinology, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
FAU - Zhang, Feng
AU  - Zhang F
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, Metabolic 
      Syndrome Research Center, Department of Metabolism and Endocrinology, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
FAU - Wang, Huiying
AU  - Wang H
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, Metabolic 
      Syndrome Research Center, Department of Metabolism and Endocrinology, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
FAU - Xie, Lijun
AU  - Xie L
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, Metabolic 
      Syndrome Research Center, Department of Metabolism and Endocrinology, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
FAU - Chen, Zhinan
AU  - Chen Z
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, Metabolic 
      Syndrome Research Center, Department of Metabolism and Endocrinology, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
FAU - Zeng, Weimin
AU  - Zeng W
AD  - Key Laboratory of Biometallurgy, School of Minerals Processing and 
      Bioengineering, Ministry of Education, Central South University, Changsha, China.
FAU - Zhou, Zhiguang
AU  - Zhou Z
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, Metabolic 
      Syndrome Research Center, Department of Metabolism and Endocrinology, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
FAU - Hu, Fang
AU  - Hu F
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, Metabolic 
      Syndrome Research Center, Department of Metabolism and Endocrinology, The Second 
      Xiangya Hospital of Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20220601
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9198539
OTO - NOTNLM
OT  - glucose metabolism
OT  - guava leaf
OT  - gut microbiota
OT  - hyperglycemia
OT  - liver
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/21 06:00
MHDA- 2022/06/21 06:01
PMCR- 2022/06/01
CRDT- 2022/06/20 03:50
PHST- 2022/03/30 00:00 [received]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/06/20 03:50 [entrez]
PHST- 2022/06/21 06:00 [pubmed]
PHST- 2022/06/21 06:01 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - 907702 [pii]
AID - 10.3389/fphar.2022.907702 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jun 1;13:907702. doi: 10.3389/fphar.2022.907702. 
      eCollection 2022.